Search

Displaying results 3471 - 3480 of 10000 in total
  1. Drug

    Streptococcus pneumoniae type deOAc15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB19344
    ApprovedInvestigational

    Streptococcus pneumoniae type deOAc15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains de-O-acetylated saccharides of the capsular antigens of _Streptococcus … pneumoniae_ serotype 15B individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of _Corynebacterium diphtheriae_ strain C7 (β197).

  2. Drug

    Valproate bismuth

    go.drugbank.com/drugs/DB13910
    Approved

    Valproate bismuth is available in Canada in the over-the-counter medication Neo-Laryngobis.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  3. Drug

    DS-2325a

    go.drugbank.com/drugs/DB18134
    Investigational

    DS-2325a is an inhibitor of kallikrein 5 under development for the treatment of Netherton Syndrome.

  4. Drug

    Gonadorelin

    go.drugbank.com/drugs/DB00644
    ApprovedInvestigationalVet approved

    It is a synthetic decapeptide prepared using solid phase peptide synthesis. GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pituitary.

  5. Drug

    N-methylnicotinamide

    go.drugbank.com/drugs/DB08840
    Investigational

    N-methylnicotinamide is an experimental drug with no approved indication or marketed formulation. … It is a metabolite of niacinamide/nicotinamide and niacin/nicotinic acid (vitamin B3), and as such N-methylnicotinamide is used to diagnose niacin deficiency by measuring N-methylnicotinamide in the urine

  6. Drug

    Midostaurin

    go.drugbank.com/drugs/DB06595
    ApprovedInvestigational

    It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents. … Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3.

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  7. Drug

    Taurocholic acid

    go.drugbank.com/drugs/DB04348
    Approved

    The product of conjugation of cholic acid with taurine. Its sodium salt is the chief ingredient of the bile of carnivorous animals. … It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    OSU-6162

    go.drugbank.com/drugs/DB19178
    Investigational

    OSU-6162 is under investigation in clinical trial NCT05641623 (OSU6162 as Add-on in Ssri/snri-resistant Depression).

    Categories: Dopamine D2 Receptor Antagonists
  9. Drug

    Deoxycholic acid

    go.drugbank.com/drugs/DB03619
    ApprovedInvestigational

    In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity. … Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that

  10. Drug

    Chymotrypsin

    go.drugbank.com/drugs/DB09375
    ApprovedInvestigationalVet approvedWithdrawn

    Chymotrypsin (EC 3.4.21.1) is a digestive enzyme that promotes proteolysis, or the breakdown of proteins and polypeptides. … It is a serine protease synthesized in the pancreas and is a vital component in the pancreatic juice.

    Synonyms: Chymotrypsin A